The Michael J. Fox Foundation for Parkinson's Research

Thank you to our 2025 Parkinson’s Disease Therapeutics Conference (PDTC) Silver Sponsors. We were so fortunate to have the support of Alamar Biosciences, Inc., Arvinas, Gain Therapeutics, GE HealthCare, MeiraGTx, Merck, Mitsubishi Tanabe Pharma America, Join Parachute, Prevail Therapeutics, PsychoGenics, and TRIDENT Preclinical Trials. If you’re interested in learning more about how to get involved or support next year’s event, please reach out to pdtc@michaeljfox.org.

October 20–26 is National Estate Planning Awareness Week (NEPAW). It’s a reminder that planning ahead is about more than finances — it’s about protecting your future, caring for loved ones and ensuring your wishes are honored. At The Michael J. Fox Foundation, our Planned Giving team works closely with the Parkinson’s community to make estate planning approachable. We help people understand how creating or updating a will can reflect personal values, provide peace of mind and even support progress toward a cure. As part of NEPAW, we invite you to join our virtual talk: Planning Ahead: Retirement After a Parkinson’s Diagnosis, hosted by Leo E Priemer, CFP®, CEPA®, AAMS™ of Edward Jones, featuring Ethan Henderson. He’ll share practical steps and resources to help you make informed decisions — from navigating retirement after a diagnosis to preparing for long-term care. Register today at https://bit.ly/4nkOayf

Join us in congratulating the Edmond J. Safra Fellowship's class of 2025! These newly graduated movement disorder specialists will provide expert care to hundreds of Parkinson's patients every year and move forward research breakthroughs. The fellowship program funds academic centers worldwide to train new movement disorder clinician-researchers to ensure more neurologists receive vital training in Parkinson’s and related conditions. Meet the class of 2025 and learn more about the fellowship: https://bit.ly/3dWPGZC

Our final Parkinson’s IQ + You event of 2025 brought us to Honolulu, Hawaii, and we couldn’t imagine a more meaningful way to close out the year. To everyone who joined us in 2025, thank you. From coast to coast, it has been a privilege to meet this incredible community — all eager to learn, connect and take action. A special thank you to our moderator, Allison Signorelli, for leading powerful conversations and sharing her personal experiences with honesty and heart. We’re already looking ahead to 2026 and can’t wait to announce where Parkinson’s IQ + You is headed next!

Join Jimmy Choi this Thursday, October 16, at 12 p.m. ET as he moderates our upcoming webinar on treatment options for progressing Parkinson’s. This Third Thursdays Webinar will cover medication options for managing Parkinson’s symptoms and “off” time, with a special focus on the two infusion pumps that the U.S. Food and Drug Administration has approved within the last year. Register here: https://lnkd.in/eiBqmRRM This webinar is brought to you with support from Mitsubishi Tanabe Pharma America.

Thank you to XellSmart Bio for supporting this year's Parkinson's Disease Therapeutics Conference. XellSmart is a biotechnology company dedicated to developing scalable, low-cost, allogeneic stem cell therapies derived from induced pluripotent stem cells (iPSCs) to treat major degenerative diseases with high unmet medical need. XellSmart's allogeneic iPSC-derived cell therapies, XS411 and XS228, targeting Parkinson's disease and ALS, have been approved to enter Phase I clinical trials in both the United States and China.

Michael J. Fox continues to exemplify what real optimism and persistence look like — in life, in his writing, through the work of The Michael J. Fox Foundation for Parkinson's Research, and yes, maybe even back on television. I'm proud to call him a friend and partner in our mission to end Parkinson’s.   Check out his latest feature in PEOPLE Magazine | PEOPLE.com, highlighting his new memoir Future Boy and the powerful story he continues to write. https://shorturl.at/mBSU6 #FutureBoy

Advancing Parkinson’s disease research takes collaboration. Through our new Parkinson’s Disease Research Exchange (PDRx), The Michael J. Fox Foundation convenes scientists from academic labs, industry partners and clinics in a weekly virtual consortium — with a strong focus on pre-clinical research — to share discoveries and drive solutions. Join our online platform today to collaborate, exchange ideas and shape research. https://lnkd.in/ePQtzwg4

Thank you to Sumitomo Pharma America, Inc. for supporting the 2025 Parkinson's Disease Therapeutics Conference. Sumitomo Pharma delivers innovative treatments, scientific expertise and advanced technology to address patient needs across oncology, women's health, urology, rare diseases, CNS disorders and cell & gene therapies. Their program, DSP-1083/CT1-DAP001, is a regenerative cell therapy currently in Phase 1/2 clinical development for Parkinson's disease that uses induced pluripotent stem cell (iPSC)-derived dopaminergic progenitor cells to replace damaged neurons. https://lnkd.in/evreBpiM